DEVICE CATEGORY · OOB
Drug-Eluting Percutaneous Transluminal Coronary Angioplasty Catheter
A drug-eluting percutaneous transluminal coronary angioplasty catheter is a combination product intended for balloon dilatation of a hemodynamically significant coronary artery or bypass graft stenosis in patients evidencing coronary ischemia for the purpose of improving myocardial perfusion. A drug-eluting ptca catheter may also be intended for the treatment of acute myocardial infarction; Treatment of in-stent restenosis (isr) and/or post-deployment stent expansion. A drug-eluting ptca catheter delivers a drug to the vessel as part of the angioplasty procedure, which is intended to inhibit restenosis.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
SELUTION SLR 014 PTCA Drug-Eluting BalloonP250041/S001 | MedAlliance, LLC | PMA supplement | Nov 6, 2026 | FDA |
| MedAlliance, LLC | PMA approval | Sep 18, 2026 | FDA | |
AGENT Paclitaxel-Coated Balloon CatheterP230035/S010 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Aug 28, 2026 | FDA |
AGENT Paclitaxel-Coated Balloon CatheterP230035/S009 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Jul 30, 2026 | FDA |
AGENT Paclitaxel-Coated Balloon CatheterP230035/S006 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Feb 11, 2026 | FDA |
AGENT Paclitaxel-Coated Balloon CatheterP230035/S007 | BOSTON SCIENTIFIC CORPORATION | PMA supplement | Oct 24, 2025 | FDA |
Source information
Follow the FDA links to view the original records.


